GlassScriptPhysician profile
Steven Safran
NPI 1386624864
$31,383.95
in general payments reported to CMS, 2019-2025
21 companies · $476 in 2025
The $476 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,706 · 2020: $12K · 2021: $817 · 2022: $1,635 · 2023: $6,894 · 2024: $831 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,175 · Food and Beverage: $1,990 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,175.00 |
| Food and Beverage | $1,990.44 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $12,666.36 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Cynosure, LLC | $11,879.50 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,183.97 | 2019-2021 | |
| Allergan, INC. | $1,119.52 | 2019-2022 | |
| Sight Sciences, INC. | $910.85 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $560.25 | 2019-2025 | Idosetr |
| Bausch & Lomb Americas INC. | $482.40 | 2022-2024 | Envista Mx60 Iol, Stellaris, Stellaris |
| Carl Zeiss Meditec, INC. | $454.19 | 2019-2023 | |
| Ivantis, INC | $227.27 | 2019-2021 | |
| Rxsight INC | $206.72 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Sun Pharmaceutical Industries INC. | $173.36 | 2019-2022 | |
| Abbvie INC. | $142.93 | 2022-2023 | Xen Glaucoma Treatment System |
| Alcon Vision LLC | $95.20 | 2023 | Hydrus Microstent |
| New World Medical,INC. | $55.74 | 2019 | |
| Biotissue Holdings INC. | $45.47 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $43.19 | 2024 | Artevo 800 |
| Dompe US, INC. | $38.63 | 2022 | |
| Samsara Vision | $27.86 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.35 | 2019 | |
| Aerie Pharmaceuticals, INC. | $26.84 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Safran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.